

Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts

Taek-Kyun Kwon^{1,*}, Jae-Min Song^{1,*}, In-Ryoung Kim², Bong-Soo Park², Chul-Hoon Kim³,
In-Kyo Cheong¹, Sang-Hun Shin¹

Departments of ¹Oral and Maxillofacial Surgery and ²Oral Anatomy and Cell Biology, School of Dentistry, Pusan National University, Yangsan, ³Department of Dentistry, Dong-A University Hospital, Busan, Korea

Abstract (J Korean Assoc Oral Maxillofac Surg 2014;40:291-296)

Objectives: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a side effect of bisphosphonate therapy that has been reported in recent years. Osteoclastic inactivity by bisphosphonate is the known cause of BRONJ. Bone morphogenetic protein-2 (BMP-2) plays an important role in the development of bone. Recombinant human BMP-2 (rhBMP-2) is potentially useful as an activation factor for bone repair. We hypothesized that rhBMP-2 would enhance the osteoclast-osteoblast interaction related to bone remodeling.

Materials and Methods: Human fetal osteoblast cells (hFOB 1.19) were treated with 100 μ M alendronate, and 100 ng/mL rhBMP-2 was added. Cells were incubated for a further 48 hours, and cell viability was measured using an MTT assay. Expression of the three cytokines from osteoblasts, receptor activator of nuclear factor- κ B ligand (RANKL), osteoprotegerin (OPG), and macrophage colony-stimulating factor (M-CSF), were analyzed by real-time polymerase chain reaction and enzyme-linked immunosorbent assay.

Results: Cell viability was decreased to 82.75% \pm 1.00% by alendronate and then increased to 110.43% \pm 1.35% after treatment with rhBMP-2 (P <0.05, respectively). OPG, RANKL, and M-CSF expression were all decreased by alendronate treatment. RANKL and M-CSF expression were increased, but OPG was not significantly affected by rhBMP-2.

Conclusion: rhBMP2 does not affect OPG gene expression in hFOB, but it may increase RANKL and M-CSF gene expression.

Key words: Bone morphogenetic protein-2, Alendronate, Osteoblasts, Macrophage colony-stimulating factor, RANK ligand

[paper submitted 2014. 7. 29 / accepted 2014. 9. 2]

I. Introduction

Bisphosphonates (BPs) are used to treat osteoporosis, bone metastasis and other conditions involving fragile bone. Oral BPs are used primarily in the treatment of osteoporosis, and alendronate is one of the most potent antiosteoporotic agents known. As a side effect of using BPs, BP-related osteonecrosis of the jaw (BRONJ) was reported in 2003; in the field of

oral and maxillofacial surgery, it is one of the most difficult diseases to treat¹.

Alendronate pharmacologically inhibits farnesyl diphosphate synthase in the mevalonate pathway, which is essential for the prenylation of proteins in osteoclasts. This ultimately causes mechanical inhibition of osteoclast adhesion on the bone margin where absorption takes place through osteoclast apoptosis. The effect of BPs on osteoclasts could also arise, at least in part, from modulation of the synthesis of resorption-promoting or resorption-inhibiting factors by osteoblasts². Osteoblast/stromal cells regulate osteoclastogenesis by producing proteins such as macrophage colony-stimulating factor (M-CSF), receptor activator of nuclear factor- κ B ligand (RANKL), and osteoprotegerin (OPG). Through cell-to-cell contact of osteoblast/stromal cells with osteoclasts, RANKL and M-CSF induce osteoclast progenitor cells to differentiate into osteoclasts³.

Sang-Hun Shin

Department of Oral and Maxillofacial Surgery, Pusan National University Dental Hospital, 20 Geumo-ro, Mulgeum-eup, Yangsan 626-770, Korea
TEL: +82-55-360-5113 FAX: +82-55-360-5104
E-mail: ssh8080@pusan.ac.kr

*These authors contributed equally to this study as first authors.

©This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2014 The Korean Association of Oral and Maxillofacial Surgeons. All rights reserved.

This work was supported by 2-Year Research Grant of Pusan National University.

Bone morphogenetic protein (BMP), a subgroup of the transforming growth factor- β (TGF- β) superfamily⁴, induces the formation of bone and cartilage⁵⁻¹⁰. To date, there are more than 20 known BMP subgroups, of which BMP-2 is the primary subgroup used as a clinical treatment in many *in vitro* and *in vivo* studies¹¹. Recombinant human BMP-2 (rh-BMP-2) is an activation factor for bone healing and has been used in dentistry due to its osteogenic effects.

The aim of the present study was to explore the effect of rhBMP-2 on the regulation of OPG, RANKL, and M-CSF in osteoclastogenesis in human osteoblast treated with alendronate.

II. Materials and Methods

1. Reagents

The following reagents were commercially obtained: Pro-Long Gold Antifade Reagent with DAPI, from Molecular Probes (Eugene, OR, USA); Dulbecco's modified Eagle's medium F12 (DMEM/F12) and fetal bovine serum (FBS), from Gibco (Gaithersburg, MD, USA); Alendronate, Dimethyl sulfoxide (DMSO), Hoechst 33342, RNase A, proteinase K, aprotinin, leupeptin, Triton X-100, PMSF and thiazolyl blue tetrazolium bromide (MTT), from Sigma (St. Louis, MO, USA); SuperSignal West Femto enhanced-chemiluminescence Western blotting detection reagent, from Pierce (Rockford, IL, USA).

2. Cell culture

An hFOB 1.19 human fetal osteoblast cell line was purchased from the American Type Culture Collection (Rockville, MD, USA). The cells were maintained at 34°C with 5% CO₂ in DMEM/F12 with 4 mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose and 1.0 mM sodium pyruvate supplemented with 10% FBS, under an air atmosphere.

3. Cell viability assay

A total of 1×10⁴ cells were seeded in a 96-well plate, incubated for 24 hours, and treated with 0, 100, 500 or 1,000 μ M concentrations of alendronate. The cells were then treated with 500 μ g/mL of MTT stock solution and incubated at 34°C in a 5% CO₂ atmosphere for 4 hours. The medium was aspirated, and the formazan crystals were dissolved in DMSO. Cell viability was monitored on an enzyme-linked immunosorbent

assay (ELISA) reader (Tecan, Männedorf, Switzerland) at a 570 nm excitatory emission wave length. In cells treated with 100 μ M alendronate, cell viability was approximately 80% of the control. Consequently, that concentration was selected for the experimental group.

4. ELISA

Expression levels of the three proteins, RANKL, OPG and M-CSF, were measured with an ELISA kit (Quantikine; R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Briefly, cultured hFOB 1.19 cells were uniformly seeded into 6-well culture dishes at a concentration of 2×10⁵ cells/well. When the cells were adherent 24 hours later, the original medium was replaced with medium containing 100 μ M alendronate for 48 hours (alendronate group) after which 100 ng/mL BMP-2 (Cowellmedi, Busan, Korea) was added, and the cells were incubated for a further 48 hours (alendronate+rhBMP-2 group). The supernatants were then collected from each group, and an ELISA was used to determine the RANKL, OPG and M-CSF contents of each sample. The sample values were read from the standard curve set at 450 nm with 540-570 nm wavelength correction and with the measurement units expressed as pg/mL. All samples were assayed simultaneously.

5. Real-time polymerase chain reaction (RT-PCR)


The hFOB 1.19 cells were subjected to RNA extraction using spin columns (Rneasy; Qiagen, Hilden, Germany) according to the manufacturer's instructions. RNA (2 μ g) was reverse-transcribed, using the RevertAid First-Strand Synthesis System kit for RT-PCR (Thermo Fisher Scientific, Pittsburgh, PA, USA) according to the manufacturer's protocol. The cDNA was amplified with the PCR master mix SYBR Green kit (Applied Biosystems, Warrington, UK), and PCR amplification was performed using the Chromo4 Real-Time PCR Detection System (Bio-Rad Laboratories Inc., Hercules, CA, USA). The running conditions were as follows: denaturing at 95°C for 3 minutes, 40 cycles of amplification at 95°C for 15 seconds and 60°C for 30 seconds. After the final cycle, a melting curve analysis was performed at 55°C-95°C intervals in 0.5°C steps. The sense and anti-sense primer sequences of OPG, RANKL, M-CSF, and the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) are listed in Table 1.

Table 1. Primers used in this study

Gene	Sense (5'-3')	Antisense (5'-3')
RANKL	GATGAAAGGAGGAAGCACCA	TAAGGAGGGGTTGGAGACCT
OPG	TGCAGTACGTCAAGCAGGAG	AGGCAGCTCCTATGTTTCA
M-CSF	GGAGACCTCGTGCCAAATTA	TATCTCTGAAGCGCATGGTG
GAPDH	CAATGACCCCTTCATTGACC	GACAAGCTTCCCCTTCTCAG

(RANKL: receptor activator of nuclear factor- κ B ligand, OPG: osteoprotegerin, M-CSF: macrophage colony-stimulating factor, GAPDH: glyceraldehyde 3-phosphate dehydrogenase)

Taek-Kyun Kwon et al: Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts. *J Korean Assoc Oral Maxillofac Surg* 2014

**Fig. 1.** Cell viability of various alendronate concentrations in hFOB 1.19.

Taek-Kyun Kwon et al: Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts. *J Korean Assoc Oral Maxillofac Surg* 2014

6. Statistical analysis

Groups were comparatively analyzed by one way ANOVA. Tukey's *post hoc* test was used for cell viability and RT-PCR (SPSS Statistics 17.0; SPSS Inc., Chicago, IL, USA). $P < 0.05$ was considered statistically significant.

III. Results

1. Viability of hFOB 1.19 cells

An MTT assay was performed at 48 hours with 0, 100, 500, 1,000 μ M alendronate concentrations. (Fig. 1) Alendronate inhibited cellular viability at 100 μ M ($P < 0.05$). When the cells were exposed to concentrations above 100 μ M, there was a significant decrease in cell viability ($P < 0.05$).

To investigate the reverse effects of rhBMP-2 on cell viability, cell viability assays were repeated with application of rhBMP-2 to cells treated with 100 μ M alendronate after 48 hours. (Table 2) Cell viability significantly increased relative to the control and alendronate alone group ($P < 0.05$).

Table 2. Effects of alendronate and recombinant human bone morphogenetic protein-2 (rhBMP-2) on cell viability


Groups	Cell viability (%)
Control	100 ± 0.67
Alendronate	82.75 ± 1.00 ¹
rhBMP-2	113.50 ± 1.63 ^{1,2}
Alendronate+BMP-2	110.43 ± 1.35 ^{1,2}
<i>P</i> -value	0.000

¹Statistical significance ($P < 0.05$) compared with control group.

²Statistical significance ($P < 0.05$) compared with alendronate group.

Values are presented as mean ± standard deviation.

Taek-Kyun Kwon et al: Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts. *J Korean Assoc Oral Maxillofac Surg* 2014

**Fig. 2.** Effect of alendronate and rhBMP-2 on OPG expression. ELISA of OPG expression. (rhBMP-2: recombinant human bone morphogenetic protein-2, OPG: osteoprotegerin, ELISA: enzyme-linked immunosorbent assay)

Taek-Kyun Kwon et al: Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts. *J Korean Assoc Oral Maxillofac Surg* 2014

2. Effects of alendronate and rhBMP-2 on OPG expression

To evaluate OPG expression, RT-PCR and an ELISA were performed. OPG expression in the alendronate group was significantly decreased ($P = 0.012$) as compared to the control group. In the alendronate+rhBMP-2 group, the OPG level increased relative to alendronate group, but this increase was not significant ($P = 0.482$). (Fig. 2, Tables 3, 4)

Table 3. Expression of OPG, RANKL and M-CSF in RT-PCR

Antibody	Group				P-value
	Control	Alendronate	rhBMP-2	Alendronate+rhBMP-2	
OPG (pg/mL)	1	0.69±0.01 ¹	0.93±0.03 ²	0.80±0.16	0.007
RANKL (pg/mL)	1	0.72±0.10 ¹	1.07±0.09 ²	1.01±0.07 ²	0.000
M-CSF (pg/mL)	1	0.62±0.02 ¹	1.10±0.05 ^{1,2}	0.77±0.02 ^{1,2}	0.000

(OPG: osteoprotegerin, RANKL: receptor activator of nuclear factor-κB ligand, M-CSF: macrophage colony-stimulating factor, RT-PCR: real-time polymerase chain reaction, rhBMP-2: recombinant human bone morphogenetic protein-2)

¹Statistically significant ($P<0.05$) compared with control group.

²Statistically significant ($P<0.05$) compared with alendronate group.

Values are presented as mean±standard deviation.

Taek-Kyun Kwon et al: Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts. J Korean Assoc Oral Maxillofac Surg 2014

Table 4. Post hoc test result of OPG, RANKL and M-CSF in RT-PCR

Antibody	Group	P-value ¹
OPG	Control	Alendronate 0.012*
		rhBMP-2 0.800
		Alendronate+rhBMP-2 0.100
RANKL	Alendronate	Alendronate+rhBMP-2 0.482
	rhBMP-2	Alendronate+rhBMP-2 0.346
	Control	Alendronate 0.003*
RANKL		rhBMP-2 0.580
		Alendronate+ rhBMP-2 0.999
	Alendronate	Alendronate+rhBMP-2 0.003*
M-CSF	rhBMP-2	Alendronate+rhBMP-2 0.667
	Control	Alendronate 0.000*
		rhBMP-2 0.020*
		Alendronate+rhBMP-2 0.000*
	Alendronate	Alendronate+rhBMP-2 0.002*
	rhBMP-2	Alendronate+rhBMP-2 0.000*

(OPG: osteoprotegerin, RANKL: receptor activator of nuclear factor-κB ligand, M-CSF: macrophage colony-stimulating factor, RT-PCR: real-time polymerase chain reaction, rhBMP-2: recombinant human bone morphogenetic protein-2)

¹Tukey test.

* $P<0.05$.

Taek-Kyun Kwon et al: Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts. J Korean Assoc Oral Maxillofac Surg 2014

3. Effects of alendronate and rhBMP-2 on RANKL expression

RT-PCR and an ELISA were also performed to evaluate RANKL. In the alendronate group, RANKL expression was significantly decreased ($P=0.003$) as compared to the control. In the alendronate+rhBMP-2 group, RANKL expression was significantly increased relative to the alendronate alone group ($P=0.003$). (Fig. 3, Tables 3, 4)

4. Effects of alendronate and rhBMP-2 on M-CSF expression

To determine whether alendronate and rhBMP-2 treatment change the expression of M-CSF, RT-PCR and an ELISA were also done. In the alendronate group, M-CSF expression




Fig. 3. Effect of alendronate and rhBMP-2 on RANKL expression. ELISA of RANKL expression. (rhBMP-2: recombinant human bone morphogenetic protein-2, RANKL: receptor activator of nuclear factor-κB ligand, ELISA: enzyme-linked immunosorbent assay)

Taek-Kyun Kwon et al: Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts. J Korean Assoc Oral Maxillofac Surg 2014




Fig. 4. Effect of alendronate and rhBMP-2 on M-CSF expression. ELISA of M-CSF expression. (rhBMP-2: recombinant human bone morphogenetic protein-2, M-CSF: macrophage colony-stimulating factor, ELISA: enzyme-linked immunosorbent assay)

Taek-Kyun Kwon et al: Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts. J Korean Assoc Oral Maxillofac Surg 2014

was decreased significantly compared with the control group ($P=0.000$). In the alendronate+rhBMP-2 group, the M-CSF level was decreased significantly compared with the control group but increased significantly compared with the alendronate group ($P=0.002$). (Fig. 4, Table 3)

IV. Discussion

We investigated the effects of rhBMP-2 on osteoblasts treated with alendronate, since alendronate is the most widely prescribed oral BP and appears most likely to cause BRONJ¹². The effects of BPs on osteoclasts are well understood, and the effects of BPs on osteoclastic toxicity are thought to influence the occurrence of BRONJ. Although the majority of *in vitro* BPs studies have focused on BPs actions in osteoclastic lineage cells, recent studies have suggested that the presence of osteoblastic lineage cells is required for the anti-resorptive effects of BPs¹³. An understanding of the effects of alendronate on hFOB cells, particularly in the OPG/RANKL system, however, is lacking. To address this lack of data, the current study investigated the expression of RANKL, OPG and M-CSF in BP-treated hFOB cells.

Here, alendronate was shown to have a strong negative dose-dependent influence on the viability of osteoblasts. MTT assays performed at 48 hours with 0, 100, 500, and 1,000 μM alendronate concentrations revealed that the 100 μM concentration significantly reduced cell viability, with cell viability being approximately 80% of the control group. García-Moreno et al.¹⁴ reported that high concentrations of alendronate inhibit osteoblast proliferation in primary hFOB cells and indicated that at lower concentrations the drug did not significantly inhibit proliferative effects compared to controls ($\leq 10^{-5}$ M). The results of the current study are in agreement with García-Moreno et al.¹⁴ and further suggest that alendronate at higher concentrations affects proliferation and viability of hFOB cells.

We determined that expression of OPG, RANKL and M-CSF was significantly decreased in the alendronate-treated group. In contrast, in a human osteoblast-culture study, Koch et al.¹⁵ reported that zoledronate and ibandronate significantly induced RANKL expression.

Several studies have evaluated the impact of BPs on osteoclastogenesis. Sudhoff et al.¹⁶ reported that osteoclasts were suppressed and osteoclast apoptosis was induced in mouse bone-marrow cell (BMC) culture by the addition of M-CSF, RANKL and zoledronic acid. Kwak et al.¹⁷, having investigated a BMC/osteoblast co-culture, reported that risedronate

inhibits osteoclast differentiation and suppresses RANKL and that addition of M-CSF mediates osteoclast differentiation in a bone-marrow-derived macrophage culture, with no direct BPs-cytotoxicity effect on the osteoclasts.

Although the reasons for these differences have not been completely elucidated, the distinct effects of various BPs (pamidronate, zoledronate, and alendronate), use at different concentrations, and use of different cell lines (human vs. rat and primary vs. cancer) clearly play a role^{15,18}.

BMP-2 is well recognized as the most effective bone-induction treatment¹⁹⁻²³ and has been approved by the U.S. Food and Drug Administration. There is evidence that BMP-2 can directly influence osteoclastogenesis through osteoblast/stromal cells²⁴⁻²⁷. Itoh et al.²⁷ reported that BMP-2 enhanced the survival of purified osteoclasts supported by RANKL but not by M-CSF. In our present investigation, we found that a lower dose of rhBMP-2, 100 ng/mL, was able to induce osteoclast potency, indicating that at lower concentrations, BMP-2 can have osteoinductive potency²⁸. The alendronate+rhBMP-2 group showed significant elevation in expression levels of RANKL and M-CSF relative to the alendronate alone group. Our results show that BMP-2 induced expression of M-CSF but that RANKL was otherwise suppressed by alendronate. This suggests that decreased RANKL expression by BPs can be corrected by treatment of BMP-2.

V. Conclusion

This study was conducted to establish whether alendronate and rhBMP-2 influence the mRNA levels and protein expression levels of M-CSF, RANKL, and OPG in osteoblasts. Our results indicate that alendronate suppressed the expression of M-CSF, RANKL, and OPG and that rhBMP-2 increased BP-impaired RANKL, M-CSF, and OPG expression levels. Together with the previous results, the present study provides an experimental basis for the clinical effects of rhBMP-2 as a BRONJ-treatment modality.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. *J Oral Maxil-*

- lofac Surg 2003;61:1115-7.
- Kim HK, Kim JH, Abbas AA, Yoon TR. Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study. *Clin Orthop Relat Res* 2009;467:3121-8.
 - Aubin J, Liu F, Bilezikian J, Raisz L, Rodan G. Principles of bone biology. 2nd ed. San Diego: Academic Press; 1996.
 - Urist MR. Bone: formation by autoinduction. *Science* 1965;150:893-9.
 - Reddi AH. Bone and cartilage differentiation. *Curr Opin Genet Dev* 1994;4:737-44.
 - Reddi AH. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. *Nat Biotechnol* 1998;16:247-52.
 - Bostrom MP, Asnis P. Transforming growth factor beta in fracture repair. *Clin Orthop Relat Res* 1998;(355 Suppl):S124-31.
 - Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA. Growth factor regulation of fracture repair. *J Bone Miner Res* 1999;14:1805-15.
 - Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts). *J Tissue Eng Regen Med* 2008;2:1-13.
 - Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). *J Tissue Eng Regen Med* 2008;2:81-96.
 - Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. *Growth Factors* 2004;22:233-41.
 - Marx RE. Clinical concerns of alendronate use. *J Oral Maxillofac Surg* 2008;66:1322.
 - Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. *J Clin Invest* 1993;91:2004-11.
 - García-Moreno C, Serrano S, Nacher M, Farré M, Díez A, Mariño ML, et al. Effect of alendronate on cultured normal human osteoblasts. *Bone* 1998;22:233-9.
 - Koch FP, Merkel C, Ziebart T, Smeets R, Walter C, Al-Nawas B. Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. *Clin Oral Invest* 2012;16:79-86.
 - Sudhoff H, Jung JY, Ebmeyer J, Faddis BT, Hildmann H, Chole RA. Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysis. *Ann Otol Rhinol Laryngol* 2003;112:780-6.
 - Kwak HB, Kim JY, Kim KJ, Choi MK, Kim JJ, Kim KM, et al. Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss. *Biol Pharm Bull* 2009;32:1193-8.
 - Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH. Amino-bisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. *Calcif Tissue Int* 2008;82:191-201.
 - Suh DY, Boden SD, Louis-Ugbo J, Mayr M, Murakami H, Kim HS, et al. Delivery of recombinant human bone morphogenetic protein-2 using a compression-resistant matrix in posterolateral spine fusion in the rabbit and in the non-human primate. *Spine (Phila Pa 1976)* 2002;27:353-60.
 - Kübler NR, Würzler KK, Reuther JF, Sieber E, Kirchner T, Seibald W. Effect of different factors on the bone forming properties of recombinant BMPs. *Mund Kiefer Gesichtschir* 2000;(4 Suppl 2):S465-9.
 - Uludag H, D'Augusta D, Palmer R, Timony G, Wozney J. Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. *J Biomed Mater Res* 1999;46:193-202.
 - Linde A, Hedner E. Recombinant bone morphogenetic protein-2 enhances bone healing, guided by osteopromotive e-PTFE membranes: an experimental study in rats. *Calcif Tissue Int* 1995;56:549-53.
 - Yamamoto M, Takahashi Y, Tabata Y. Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. *Biomaterials* 2003;24:4375-83.
 - Toth JM, Boden SD, Burkus JK, Badura JM, Peckham SM, McKay WF. Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. *Spine (Phila Pa 1976)* 2009;34:539-50.
 - Kanatani M, Sugimoto T, Kaji H, Kobayashi T, Nishiyama K, Fukase M, et al. Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. *J Bone Miner Res* 1995;10:1681-90.
 - Kaneko H, Arakawa T, Mano H, Kaneda T, Ogasawara A, Nakagawa M, et al. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. *Bone* 2000;27:479-86.
 - Itoh K, Udagawa N, Katagiri T, Iemura S, Ueno N, Yasuda H, et al. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. *Endocrinology* 2001;142:3656-62.
 - Zhu W, Kim J, Cheng C, Rawlins BA, Boachie-Adjei O, Crystal RG, et al. Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro. *Bone* 2006;39:61-71.